Lipid Nanoparticle– tag –
-
ARPA-H Launches AEGIS Project: Affordable Gene-Editing Therapies for Pediatric Immune Diseases via CRISPR and LNP Delivery
Princeton University USA Overview The ARPA-H THRIVE-funded AEGIS project is pioneering the development of affordable gene-editing therapies for children suffering from rare inborn errors of immunity (IEIs). By leveraging advanced CRISPR ... -
bioRxiv Preprint: TLS11a Aptamer-Functionalized LNP Platform for Hepatocyte-Preferential mRNA Delivery and CRISPR LDLR-KO Model Established
bioRxiv USA Overview A preprint published in bioRxiv details the design and validation of an aptamer-functionalized lipid nanoparticle (LNP) platform for hepatocyte-preferential genome editing delivery, demonstrated using a multilevel-va... -
Beyond the Liver: Engineered LNPs Achieve Precision Cardiac Delivery for SCD1 Inhibitor Aramchol
PR Newswire Israel Overview Galmed, in collaboration with Barcode Nanotech, has developed a groundbreaking lipid nanoparticle (LNP) formulation that precisely redirects its SCD1 inhibitor, Aramchol, from liver hepatocytes to cardiac musc... -
LNP Innovation Revolutionizes RNA Delivery: Advancing Tissue-Specific Targeting and Immunoprofile Optimization
Inside Therapeutics USA Overview Lipid nanoparticles (LNPs) have established themselves as the most clinically validated and advanced platform for RNA drug delivery. LNPs critically protect nucleic acids from enzymatic degradation, facil... -
Frontiers Review Highlights RNA-Based Drugs’ Transformative Role in Modern Medicine, Emphasizing siRNA, mRNA, and ASO Delivery Strategies
Frontiers Switzerland Overview A Frontiers review comprehensively outlines the evolution of RNA therapeutics into innovative medical approaches by directly targeting disease-related RNA molecules. The review highlights the mechanisms of ... -
siRNA Overcomes Gene Silencing Challenges with LNP and GalNAc Conjugation, Expanding Therapeutic Applications
Inside Therapeutics USA Overview Inside Therapeutics details how siRNA, while offering transformative gene silencing, is overcoming delivery challenges through lipid nanoparticles (LNP) and N-acetylgalactosamine (GalNAc) conjugation tech... -
Investor Focus: RNA Platform Success Hinges on Extrahepatic Delivery Capabilities Beyond the Liver
Bioprocess Online USA Overview Bioprocess Online highlights that a key question for investors evaluating RNA therapeutic platforms is the ability to effectively deliver RNA to diverse extrahepatic organs. While current successes often le... -
Patient-Specific Lymphoid Organ Chips Recapitulate mRNA Vaccine Immune Response, Accelerating Preclinical Evaluation
Wyss Institute USA Overview Researchers at the Wyss Institute have developed an innovative technology capable of replicating mRNA vaccine-induced immune responses on patient-specific Lymphoid Organ Chips. This human-derived, ex vivo mode... -
RNA Medicines Enter ‘Second Act’ Post-COVID-19, Focusing on Extrahepatic Delivery Beyond the Liver
European Biotechnology Magazine Germany Overview RNA therapeutics are entering a 'second act' after the success of mRNA vaccines during the COVID-19 pandemic, with a critical focus on developing effective delivery technologies to extrahe... -
Nanopore-Mediated Assembly Enables Precise and Continuous Synthesis of mRNA-Encapsulated Lipid Nanoparticles, Accelerating COVID-19 Vaccine Development
ACS Nano (ACS Publications) USA Overview This research presents a nanopore-mediated assembly method for the precise and continuous synthesis of mRNA-encapsulated lipid nanoparticles (LNPs), critical for COVID-19 vaccines and other RNA th...
